Compare Gilead Sciences, Inc. (GILD) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Trade Desk Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Trade Desk Inc trades at $12.4 (market cap $5.72B). The key difference: Gilead Sciences, Inc. is far larger — about 31.8× Trade Desk Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Trade Desk Inc for 72 Days on average.
| GILD | TTD | |
|---|---|---|
Market Cap | $182.09B | $5.72B |
Volume | 4,960,247 | 14,380,236 |
Sector | Health | Media |
52-Week High | $155.80 | $54.13 |
52-Week Low | $116.74 | $11.92 |
Typical Hold Time | 111 Days | 72 Days |
Enterprise Value | $205.15B | $4.66B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
TTD trades at $12.34, down 3.52% today and 68% year-to-date, reflecting bearish technical signals and recent earnings misses. Revenue grew to $2.90B in 2025 with a 15.3% net margin, but 2026 guidance indicates slowing growth. The stock faces pressure from competition and index removal flows, with analyst consensus at a $14.72 price target amid mixed sentiment.
Outlook remains cautious due to competitive threats and slowing revenue growth, though valuation ratios appear low. Key risks include execution challenges and macroeconomic headwinds, while potential upside hinges on market share retention and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
